Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events
- Registration Number
- NCT05085665
- Lead Sponsor
- Washington University School of Medicine
- Brief Summary
This study seeks to determine which Loa loa antigens are released into circulation when infected individuals are treated with ivermectin.
- Detailed Description
A cohort of up to 50 participants with Loa loa microfilarial levels between 5,000 and 18,000 per ml/blood will be treated with ivermectin in an inpatient setting. Participants will be monitored for treatment-related adverse events for seven days post-treatment, and will have blood drawn on days 0, 1, 2, 3, and 7 post-treatment to assess for microfilarial load, cytokine, and antigen levels.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 41
- Loa loa blood microfilariae of between 5,000 - 18,000 per mL
- known allergy to ivermectin; severe comorbidities
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Ivermectin Ivermectin All eligible participants received a single dose (150 ug/kg) ivermectin by mouth
- Primary Outcome Measures
Name Time Method Cross-reactive Antigenemia 7 days N of participants with detectable Loa loa antigens in sera that cross-react with diagnostic tests for lymphatic filariasis (Filariasis Test Strip) on either day 1, 2, 3, or 7 post-treatment
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Centre de Recherche sur les Filarioses et autres Maladies Tropicales (CRFilMT)
🇨🇲Yaoundé, Cameroon